IL2 and type 1 diabetes mellitus: The efficacy of LD IL-2 was tested for the first time in a phase 1/2, double-blind, randomized, placebo-controlled trial with 24 T1D patients who were in an age range of 18–55 years and positive for at least one diabetes-associated autoantibody (15).